JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $35
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) and raises the price target from $28 to $35.
July 06, 2023 | 11:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protagonist Therapeutics' price target has been raised from $28 to $35 by JMP Securities, maintaining a Market Outperform rating.
The news of JMP Securities raising the price target for Protagonist Therapeutics while maintaining a Market Outperform rating is likely to have a positive impact on the company's stock in the short term. Investors may see this as a sign of confidence in the company's future performance, potentially driving up demand for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100